In the current study, using large numbers of patients and employing multiple layers of validation, we have demonstrated that VISTA gene expression in bone marrow samples is an independent prognostic factor in patients with both newly diagnosed (NDMM) as well as relapsed refractory MM (RRMM). This evidence concerns the gene VSIR and Miyoshi myopathy.